Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus

Exclusion Criteria

• •Active internal bleeding or recent (\< 6 months) major bleeding event requiring surgical procedure or transfusion
• •History of intracranial, intraocular, spinal bleeding or known intracranial neoplasm, arteriovenous malformation, or aneurysm
• •Severe, disabling stroke (modified Rankin score of 4 to 5, inclusive) within 3 months
• •Planned invasive procedure with potential for uncontrolled bleeding
• •Impaired hemostasis such as known International Normalized Ratio (INR) \>1.5; past or present bleeding disorder (including congenital bleeding disorders such as von Willebrand's disease or hemophilia, acquired bleeding disorders, and unexplained clinically significant bleeding disorders), thrombocytopenia (platelet count \<100,000/μL)
• •Severe chronic renal failure (creat. clearance\<30ml/min)
• •Known significant liver disease
• •Device related thrombus (mechanical valve prosthesis, left atrial appendage or septal closure devices, pacemaker leads)
• •Patients with mechanical valve prosthesis
• •Cardiogenic shock
• •Pregnancy or breast-feeding patient
• •Known allergy or hypersensitivity to VKA or DOA drugs
• •Inability or unwillingness to comply with study-related procedures
• •Participation in another clinical research protocol with other investigational agents or devices within the previous 30 days, planned use of investigational drugs or devices, or previous enrolment in this trial (participation in a trial of routine care is authorized at the same time)
• •Patient under tutorship or curatorship